Today: 9 June 2026
Exxon to Be Watched Monday After Oil Rally and Court Ruling
18 May 2026
2 mins read

Exxon to Be Watched Monday After Oil Rally and Court Ruling

New York, May 17, 2026, 18:01 EDT

  • Exxon Mobil finished Friday at $157.92, gaining 3.4% for the session. Shares were up every day in the May 11-15 week.
  • Oil led the gains. Brent crude ended Friday at $109.26 a barrel, and West Texas Intermediate closed at $105.42.
  • U.S. markets are closed for the weekend, not because of a holiday. NYSE’s next scheduled holiday is Memorial Day on May 25.

Exxon Mobil goes into Monday trading close to last week’s highs. The stock got a boost Friday as crude oil climbed and energy names moved up. A Texas jury verdict also took one legal risk off the table for the largest U.S. oil producer.

Exxon shares ended Friday at $157.92, higher than $152.78 on Thursday and $149.68 at Monday’s close, based on the company’s historical price page with LSEG numbers. Trading hit 27.9 million shares Friday, making it the week’s busiest session.

Chevron climbed 2.4% and ConocoPhillips was up 2.9% on a down day for stocks. The Energy Select Sector SPDR Fund added 2.4%. The SPDR S&P 500 ETF, which tracks the broad market, fell 1.2%.

Oil moved up Friday, with Brent up 3.35% and WTI advancing 4.2%, according to Reuters. Both benchmarks ended the week higher as traders reacted to increased shipping risks around the Strait of Hormuz. Around 20% of global oil and LNG shipments typically pass through the strait, Reuters said.

Commerzbank analysts told Reuters that “the tone between the U.S. and Iran has once again become significantly more confrontational.” Market attention is on the “tail risk of renewed military escalation,” according to Vandana Hari of Vanda Insights, also in comments to Reuters. Reuters

Exxon’s upstream business gets a boost when crude prices rise. That can mean higher earnings from oil and gas production. Still, the connection isn’t straight forward. Refining margins, shipping, hedging, project schedules and taxes all play a role and can muddle how oil prices move the stock.

Exxon’s first quarter numbers made it clear. The oil giant reported $4.2 billion in earnings, or $1.00 per share, with adjusted earnings at $4.9 billion, or $1.16 per share. Shareholder distributions totaled $9.2 billion, made up of dividends and buybacks.

Exxon CEO Darren Woods said the quarter proved Exxon is “built to perform through disruption and across market cycles.” Woods also pointed to events in the Middle East, saying they tested the company and employee safety came first. Exxon Mobil Corporation

Legal news also moved the stock. A jury in Texas cleared Exxon of liability in a case over investor claims tied to Canadian oil sands and Rocky Mountain gas assets, Reuters said. The suit from 2016 accused Exxon of hiding details about reserve valuations and accounting.

Governance is in focus this week as Exxon heads into its annual meeting on May 27. The company wants shareholders to approve shifting its legal registration from New Jersey to Texas, a process called redomiciling. Exxon says it’s “a Texas corporation in all but name.” Exxon Mobil Corporation

The vote is facing pushback. Institutional Shareholder Services is telling investors to vote no on the proposal, according to Reuters. ISS says the change might make it harder for shareholders to hold directors and officers to account.

But risks go both directions. If oil falls on signs that Hormuz shipping is coming back or if there’s a diplomatic pause, part of Friday’s buying could come out. Higher bond yields or new inflation worries could also weigh on Exxon, even if energy holds up.

Exxon has three weekend factors coming into Monday — stronger oil prices, a resolved legal issue, and a coming shareholder dispute. Those are enough to keep Exxon in focus ahead of the 9:30 a.m. EDT open.

Stock Market Today

  • $150M Cancer Proteomics Deal Spurs New NYSE Listing
    June 9, 2026, 9:34 AM EDT. A $150 million deal in functional proteomics, the study of protein functions and interactions critical for drug development, has led to the spin-out of a new company set to list on the New York Stock Exchange (NYSE). The company focuses on advanced cancer treatments including antibody-drug conjugates-targeted therapies combining antibodies with cell-killing agents to attack tumors precisely. Immunotherapies and targeted therapies featured in the pipeline aim to harness and guide the immune system to combat cancer effectively. Filing of the registration statement with regulators marks a key step toward public investment, enabling transparency. This development highlights the growing financial and clinical importance of proteomics in oncology and the biotech sector.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
QuantumScape Stock Ends Volatile Week Down; Bulls Still Looking for Key Catalyst
Previous Story

QuantumScape Stock Ends Volatile Week Down; Bulls Still Looking for Key Catalyst

Rigetti Stock Struggles, Demand for Answers Grows
Next Story

Rigetti Stock Struggles, Demand for Answers Grows

Go toTop